Sunday, July 6, 2025 7/6/2025

Comparative testing of tatCN19o for neuroprotection in rodent tMCAo

Award Number: U44NS132339
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/15/2023
PERIOD OF PERFORMANCE END DATE: 03/31/2026

Group Awards By:

View Award Description

Comparative testing of tatCN19o for neuroprotection in rodent tMCAo - Project Summary/Abstract Focal cerebral ischemia (stroke) afflicts nearly 800,000 Americans each year and often results in permanent cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have largely resulted in disappointment: the only approved pharmacological therapy is hemolytic treatment with tissue plasminogen activator (tPA; alteplase). In this project, we will further develop our optimized CaMKII inhibitor peptide tatCN19o as a cerebroprotective stroke treatment through comparative testing within the NINDS Stroke Preclinical Assessment Network (SPAN). The 30 amino-acid peptide is selective, stable, potent, water soluble, and has excellent chemistry, manufacturing, and control (CMC) properties. Importantly, tatCN19o was highly effective in vivo in global cerebral ischemia (GCI) models in both mouse and pig (the latter unpublished), even at extremely low doses of 0.01-0.02 mg/kg i.v.. The parent compound was also effective in vivo in a mouse model of acute ischemic stroke (transient middle cerebral artery occlusion; tMCAo). Neuroprotection was seen even at the latest time points tested so far after the various ischemic/excitotoxic insults (0.5h after global cerebral ischemia; 1h after stroke model; 6h in neuronal cultures). Here, SPAN will provide rigorous, unbiased testing of tatCN19o in rodent tMCAo models for direct comparison to other candidate interventions. Several tMCAo conditions are proposed for consideration by the network: compatibility with hemolytic tPA treatment (the current standard of care) and efficacy after varied insult duration. To most appropriately represent clinical populations, we propose parallel testing in adult and older animals of both sexes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $299,550 )
2025	2025	NEUREXIS THERAPEUTICS, INC.	12635 E MONTVIEW BLVD	AURORA	CO	80045	ADAMS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	4/29/2025	NON-COMPETING CONTINUATION	$299,550
														Subtotal = $299,550

Issue Date FY: 2024 ( Subtotal = $299,550 )
2024	2024	NEUREXIS THERAPEUTICS, INC.	12635 E MONTVIEW BLVD	AURORA	CO	80045	ADAMS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	3/19/2024	NON-COMPETING CONTINUATION	$299,550
2024	2024	NEUREXIS THERAPEUTICS, INC.	12635 E MONTVIEW BLVD	AURORA	CO	80045	ADAMS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	9/11/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $299,550

Issue Date FY: 2023 ( Subtotal = $299,550 )
2023	2023	NEUREXIS THERAPEUTICS INC	12635 E MONTVIEW BLVD	AURORA	CO	80045	ADAMS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	4/12/2023	NEW	$299,550
														Subtotal = $299,550

Grand Total All Awards = $898,650

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Comparative testing of tatCN19o for neuroprotection in rodent tMCAo

Award Number: U44NS132339

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/15/2023

PERIOD OF PERFORMANCE END DATE: 03/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer